Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Medical error is a leading cause of death in the United States—and physician burnout and poor well-being are playing a role, according to a recent study published in Mayo Clinic Proceedings.
After the Affordable Care Act (ACA) designated behavioral health as an essential health benefit, coverage for services rose significantly from 2013 to 2014, according to a study published July 9 in Health Affairs.
Guerbet announced Tuesday, July 10, that it has signed an exclusive agreement to collaborate with IBM Watson Health and develop artificial intelligence (AI) software solutions that help detect, diagnose and treat liver cancer.
Commercial health plans vary widely in how they cover specialty drugs, and coverage is not typically based on available evidence-based data, according to a recent study from Tufts Medical Center researchers published online July 9 in Health Affairs.
Government regulation can’t keep up with innovation in healthcare technology, especially when dealing with mobile medical applications—and those in charge of developing regulatory framework know it, according to top officials at the FDA in a July 2 viewpoint in JAMA.
The American Medical Association recognized three startups as winners in its AMA Healthcare Interoperability and Innovation Challenge. The contest awarded $50,000 in Google Cloud credits to three companies with proposals to best use patient-generated health data to improve care and reduce inefficiencies in workflows.
Higher occupancy rates in hospitals don’t necessarily mean more infections. Rather, a facility can have the highest risk for Clostridium difficile infections when capacity was in a Goldilocks zone—not too full, not too empty—between 25 and 75 percent, according to new research from the University of Michigan and RAND Corporation.
Higher occupancy rates in hospitals don’t necessarily mean more infections. Rather, a facility can have the highest risk for Clostridium difficile infections when capacity was in a Goldilocks zone—not too full, not too empty—between 25 and 75 percent, according to new research from the University of Michigan and RAND Corporation.
